Introduction
The inherited disorders of hemoglobin are the most common gene disorders, and it is estimated that 7% of the world's population are carriers. Approximately 300,000 children worldwide are born with documented SCD every year. Sickling disorders are found frequently in the Afro-Caribbean populations and sporadically throughout the Mediterranean region, India, and the Middle East. 1 Sickle-cell disease is due to a genetic mutation that results in an amino acid substitution of valine for glutamic acid at position 6 of the adult B-globin chain. In the homozygous form, this substitution results in polymerization of hemoglobin upon deoxygenation, leading to deformed dense red blood cells (RBCs) in patients with sickle-cell anemia (SCA). The predominant pathophysiological feature of homozygous SCA is vaso-occlusion, which leads to acute and chronic complications such as painful crises, increased risk of infection, acute chest syndrome, stroke, and severe pain episodes with dramatic hemolysis, which progress to involve multiple organs, including the central nervous system, cardiovascular system, lung, liver, bone, skin, and kidneys. 2 The epidemiology of SCA in the Arab region and the high prevalence of the mutation are well documented. In Saudi Arabia, the overall prevalence of the sickle-cell trait is 4.20%, with wide variation from region to region. In Oman, the prevalence of the sickle-cell trait is 6%; in Bahrain, 11.2% of the population are carriers of the sickle-cell gene. [3] [4] [5] Extensive studies conducted over several years in different provinces of Saudi Arabia have revealed a wide distribution pattern of the hemoglobin S (HbS) gene in different provinces. The overall prevalence of HbS carrier status in Saudi Arabia varies from 0 to 1% in the northern and central regions, to approximately 7% in the western, 12% in the southern, and nearly 25% in some parts of the eastern region. 6, 7 The gene frequency of HbS in the populations of the Gulf region and other Middle Eastern states is one of the highest in the world. This review will present a consensus opinion on the management of painful vaso-occlusive crisis based on the recommendations of a panel of physicians and scientists from these regions. The objective is to provide guidelines for the local practicing hematologist and nonhematologist who might not be exposed to large numbers of patients with SCA, with the goal of standardizing preventive immediate care in the emergency department, on admission, and on follow-up. The serious morbidity and hampered quality of life inflicted by painful crisis create an urgent need for well-informed guidelines for the management and treatment of patients with SCD at the local level.
Pathogenesis
The clinical hallmark of SCA is the painful acute ''crisis,'' which despite therapeutic advances, continues to be a treatment challenge. Such crises occur with variable frequency and duration, and they commonly require hospitalization. 8 The pathobiology of SCD is characterized by episodic vascular occlusion, with multiple inciting events beyond actual HbS polymerization and mechanical obstruction induced by sickled RBCs. An important mechanism of pain induction is thought to involve bone marrow vasculature infarction, leading to the release of inflammatory mediators that in turn stimulate afferent nerve fibers and cause pain. Vaso-occlusion also involves adherence of circulating blood elements, such as leukocytes, to endothelial cells, hypercoagulability, endothelial dysfunction, altered nitric oxide (NO) metabolism, and ischemia-reperfusion injury. [9] [10] [11] Increased Red Cell Adhesion Abnormal interactions between erythrocytes and endothelium are primary initiating factors in the development of microvascular occlusions in SCD. This view is supported by reports of a significant correlation between clinical severity of SCD and extent of RBC adhesiveness. 9, 12 
Increased Leukocyte Adhesion
Neutrophils are likely to be an important factor in causing microvascular sickle-cell trapping and consequent vaso-occlusion. Sickle cells appear to be more adherent to neutrophils than normal RBCs. Sickle cells also induce neutrophil oxidative activity that might be important in neutrophil-induced tissue damage during vaso-occlusive episodes. 13 
Hypercoagulability
Patients with SCD exhibit high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, reduced activity of the fibrinolytic system, and increased tissue factor expression, even in the noncrisis steady state. Platelets and other cellular elements are also chronically activated, which might predispose the patient to thromboembolic manifestations. 14, 15 Because of the increased generation of thrombin and fibrin and the increased tissue factor procoagulant activity in patients, SCD is often referred to as a hypercoagulable state. 16, 17 Recently, it was shown that compared to healthy age-and race-matched controls, patients with SCD had higher plasma levels of plasma markers of coagulation activation (D-dimers, F1þ2, and thrombin-antithrombin complex). 18 
Reperfusion Injury and NO
A central aspect of sickle-cell vasculopathy is the impairment of endothelial regulation of vasomotor tone, thrombosis, and inflammation. 9 Intermittent vascular occlusion in patients with SCA leads to reperfusion injury, which is associated with granulocyte accumulation and the enhanced production of reactive oxygen species. The recruitment of NO to counteract the resultant oxidative stress reactions results in a reduction in NO bioavailability and contributes to vascular dysfunction in SCD. 10 
Role of Inflammatory Mediators
There is an emerging consensus that a proinflammatory state contributes to the vaso-occlusive complications associated with SCD. Tissue damage due to vaso-occlusion results in the release of numerous inflammatory mediators that initiate the transmission of painful stimuli and the perception of pain. Plasma cytokines and related factors represent a burgeoning area of inquiry related to the pathogenesis of SCD. Cytokines derived from platelets, white blood cells, and endothelial cells have been implicated in the development of several sequelae of the disease. 19, 20 In as much as sicklecell adhesion to the endothelium plays a role in vaso-occlusion, the existence of such diverse mechanisms of adhesion presents an enormous challenge in terms of identifying physiologically relevant therapeutic targets. Interestingly, a recent study has suggested that targeting a specific adhesion pathway may be sufficient to reduce vasoocclusion. 21 
Clinical Presentation of the Painful Crisis Factors Precipitating Painful Crisis
Pain can be precipitated by hypoxia, infection, fever, acidosis, dehydration, pregnancy, menstruation, obstructive sleep apnea, and exposure to cold or abrupt weather changes. Coinheritance of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation also predisposes patients with SCA to pain. 22 Patients also cite anxiety, depression, alcohol consumption, and physical exhaustion. Pain can be precipitated by comorbidities such as sarcoidosis, diabetes mellitus, cholecystitis, and herpes; in many instances, no precipitating event is identified. [23] [24] [25] 
Effects of Pain on Quality of Life and Survival
Sickle-cell disease is chronic and lifelong. Individuals are most often well, but their lives are punctuated by periodic painful attacks, and they are at increased risk of other medical complications and premature death. 26 Several studies have examined the relationship between pain and quality of life, and current emphasis in treatment is on managing distress, pain relief, and psychological support. 27 The average life expectancy of males and females with SCD is 42 and 48 years, respectively. 26 Individuals who experience >6 episodes per year have a reduced survival rate compared to those who experience less frequent events. However, with good health care, many individuals with SCA maintain reasonably good health most of the time and live productive lives. In fact, in the past 30 years, the life expectancy of individuals with SCA has increased. 23 
Characteristics of Pain
The acute painful crisis is characterized by a sudden onset of pain that might start in any part of the body. The pain is variable from mild to severe with excruciating deep pain that is felt in the bones and soft tissues. Acute painful crisis is distinct from other varieties of pain that can arise due to complications of SCA, such as acute chest syndrome, priapism, splenic and hepatic sequestration, hand-foot syndrome, arthritis, and abdominal pain caused by calcular cholecystitis. Before embarking on a diagnosis of acute painful crisis, it is important that these other causes of pain be ruled out. 23 
Management of Painful Episodes

Management at Presentation
Patients should be seen immediately by a physician, and a thorough history and examination should be carried out immediately. Routine laboratory testing might not be necessary in patients with uncomplicated vaso-occlusive crises. If a patient has symptoms that are severe enough to warrant hospitalization, laboratory tests should include a complete blood count, reticulocyte count, and urinalysis. If fever is present, a chest radiograph should be obtained, and urine, sputum and blood samples should be cultured to rule out infection. Fever is common in patients with uncomplicated vasoocclusive crisis and does not necessarily indicate the presence of an underlying infection. 33 If the patient experiences severe abdominal pain, recurrent vomiting, respiratory symptoms, neurological signs of paresis or paralysis, acute joint swelling, priapism, or an abrupt fall in hemoglobin, the treating physician should be alerted, and the etiology identified and treated. 23 Comprehensive approaches to ambulatory and inpatient pain management have been addressed in a number of publications. 20, 29, 33 These reports are Home-Based Versus Hospital Treatment
The best approach to managing pain is aggressive analgesic therapy with frequent reassessment of effectiveness using a standardized pain assessment tool. The treatment of milder episodes of pain can be achieved at home with oral fluids, oral analgesics such as paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs; ibuprofen in particular for children), 37 and comfort measures such as heating pads. For the patient who has persistent pain, codeine or tramadol are recommended. When home-based management fails to adequately alleviate pain, it is essential that patients undergo rapid triage, physical assessment, and aggressive, appropriately monitored analgesia. 31 
Hospitalization
For severe pain, the patient will require hospitalization. Hydration and parenteral opioids, such as morphine, are indicated and usually administered by scheduled around-the-clock dosing or patientcontrolled analgesia. 29, 31, 33 During admission and episodes of severe pain, life-threatening complications may develop rapidly and often are heralded by relatively sudden clinical changes, such as increased oxygen requirement, altered mental status, or decreased hemoglobin levels or platelet counts. 39, 41 Guidelines for routine clinical measures to be taken at presentation are summarized in Table 1 . Opioids should not be withheld because of the unfounded fear of addiction. A recent retrospective evaluation of pain assessment and treatment for acute vaso-occlusive episodes in children with SCD concluded that despite opiate dosing within recommended guidelines, mean pain scores remained in the moderate-to-severe range for several days following hospitalization for vaso-occlusive episodes. 35 The fact that pain is severe and protracted and involves complex underlying etiologies, including impaired cellÀcell interactions, increased production of proinflammatory mediators, hemostatic imbalance, and hypercoagulability, opens the door to the development of alternative approaches to therapy, including the use of anti-adhesion, antiinflammatory, and anticoagulation agents. Recently, the LMWH tinzaparin, given as a supplement to opioid treatment, was found to significantly shorten the protracted course of pain in a randomized, controlled, double-blind study. 8 Thus, tinzaparin is justified for use in the treatment of acute painful crisis in SCA. The clinical effects of tinzaparin are most likely due to its pharmacodynamic effects on a variety of cellular factors, including endothelial tissue factor pathway inhibitor (TFPI), tumor necrosis factor-a, NO activity, von Willebrand factor (vWF), matrix degrading enzymes, and P-selectin. [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Long-lasting increases in plasma concentrations of TFPI and NO induced by tinzaparin in particular would contribute to favorable anticoagulant effects. Given once daily, tinzaparin does not require any special monitoring 8, 54, 55 (Table 2 ). However, further trials are required before making a general recommendation.
Potential Prophylaxic and Therapeutic Impact of Antithrombotic Agents in SCD
Aspirin, standard heparin, and warfarin have been used for the treatment of acute painful crisis without conclusive results. 44, 46 Tinzaparin has been show to have antithrombotic, anti-inflammatory, and vascular protective effects in obese and healthy participants and is justified in the treatment of acute painful crisis in SCA based on a randomized, double-blind clinical trial 8, 48, [51] [52] [53] (Table 2 ).
In summary, the vascular pathophysiology of SCD is due to the combination of many factors, including red and white blood cell adhesion to endothelium, increased coagulation, and homeostatic perturbation. The vascular endothelium is central to disease pathogenesis because it presents adhesion molecules for the attachment of blood cells, balances the procoagulant and anticoagulant properties of the vessel wall, and regulates vascular homeostasis by synthesizing vaso-constricting and vasodilating substances. Intermittent vascular occlusion in SCD leads to reperfusion injury, which is associated with granulocyte accumulation and enhanced production of reactive oxygen species. The recruitment of NO to counteract the resultant oxidative stress reactions results in reduced NO bioavailability and contributes to vascular dysfunction in SCD. Table 2 illustrates the impact of the LMWH tinzaparin on many of these complex processes.
Ancillary Measures
Ancillary measures to reduce the incidence of complications during acute pain crisis include the use of frequent incentive spirometry while the patient is awake to encourage deeper inspiratory effort, and avoidance of fluid overload by limiting the overall intake to 1.0 to 1.5 times the maintenance need. 56 Oxygen supplementation is not needed unless hypoxemia is present. Close monitoring of oxygen saturation and respiratory status, with particular attention to excessive sedation, is necessary. 57 Other adjuvants include antihistamines, anticoagulants, antidepressants, benzodiazepines, and anticonvulsants. This is a heterogeneous group of compounds that potentiate the analgesic and ameliorate the side effects of opioids and themselves exert mild analgesic effects. The role of selective serotonin re-uptake inhibitors in SCA is not clear at present. Adjuvants must be used with care, and patients should be monitored carefully when receiving them. Adjuvant therapy can have adverse effects, some of which precipitate or worsen the manifestations of SCA.
Other considerations include maintaining adequate (but not excessive) hydration, the provision of heating pads, massages, warm baths and other comfort measures, monitoring of oxygenation and cardiopulmonary status, and close observation of other potential complications, particularly acute chest syndrome. [56] [57] [58] [59] [60] [61] [62] [63] 
Discharge Criteria
The patient is considered ready for discharge when he or she can tolerate oral fluids and medications, pain is controlled by per oral (PO) medication, and concurrent problems are resolved. Long hospital stays are often complicated by hospital-acquired infections.
Rehabilitation and Psychological Considerations in the Management of SCD
Recurrent pain has an immeasurably negative impact on daily activities, school and work performance, social interactions and relationships, mood, quality of life, and recreation activities ( Table 3 ). The psychosocial aspects of chronic pain are complex and often are not appropriately addressed. A patient with chronic and recurrent pain must undergo a thorough psychosocial assessment to help define stressors and Exerts favorable pharmacodynamic effects as compared to other LMWHs on a variety of cellular factors, including endothelial TFPI, vWF, TNF-a, NO modulation and P/L-selectin Inhibits matrix degrading enzymes more effectively than other LMWHs Reduces oxidative stress by inhibiting the generation of reactive oxygen species Induces long-lasting increases in plasma TFPI and NO Has favorable anticoagulant efficacy and safety profiles Has a once daily pharmacokinetic profile Does not require any special dose adjustment monitoring in special patient populations, including severe renal failure patients LMWH ¼ low-molecular-weight heparin; TFPI= tissue factor pathway inhibitor; TNF ¼ tumor necrosis factor; NO ¼ nitric oxide; SCD ¼ sickle-cell disease a see refs 8,45-55. comorbidities (i.e. depression), coping strategies, and support systems. 64 Many patients with SCD have physical and psychological stressors/complications due to the disease or disease therapy. These complications can include divorce, loss of family ties and friendship, unemployment due to interruption of work, dependence on social welfare support, and stereotyping of patient problems with drug seeking behavior. Generally, there is no consistent plan for disease management and follow-up by physicians who are not experienced in the treatment of SCD. This lack of a consistent plan, in addition to the disabling complications of SCD, such as chronic pain syndrome, avascular necrosis, arthropathies, and other skeletal manifestations, can result in depression and low self-esteem. Table 3 presents an example of a well-coordinated structured program based on the physical and psychological aspects of SCD. [64] [65] [66] [67] Pregnancy and SCA Pregnancy increases the complications of SCA for the mother, fetus, and neonate, but there have been significant improvements in outcomes. [68] [69] [70] The cornerstone of management during pregnancy involves the hematologist and the obstetrician, as the mother needs regular monthly follow-ups and close fetal monitoring. All pregnant patients with SCA should receive folic acid from the beginning of pregnancy. Immunization history should be current, particularly hepatitis B, pneumococcal, and influenza vaccinations. Asymptomatic bacteriuria must be treated as well as any other active infection. Patient must be instructed to adequately hydrate and avoid physical and psychological stress.
Management of Sickle-Cell Patients during Pregnancy
Forty-eight percent of women with SCD experience a crisis during pregnancy. 69, 71 Painful sickle-cell crisis requires admission and treatment with intravenous hydration and pain control. Analgesia should be adjusted based on the patient's response, with rapid relief being the goal. NSAID are not the therapy of choice in pregnant patients who have a mild crisis because of the concern for premature closure of the ductus arteriosus at advanced gestational age. Rather, opiates, preferably morphine, are recommended. Patients should be on a scheduled dosage with additional boluses if needed. Oxygen therapy should be given if oxygen saturation is less than the patient's known steady state. Adjuvant therapy, such as stool softeners, antipruritics, and anxiolytics/sedatives should be considered. 72 Blood transfusion may be indicated if signs or symptoms of anemia are present (tachycardia, tachypnea, dyspnea, fatigue, decreasing hemoglobin, and a low reticulocyte count of <100 Â 10 9 /L). Blood should be leukopoor and antigen matched. In extreme cases, exchange transfusions may be required. 73 Table 3 . Recommended Physical and Psychosocial Services for Patients With SCA Establishment of a dedicated unit for the care of SCD Establishment of dedicated multidisciplinary team of specialized doctors, nurses, physical therapist, psychologist/psychiatrist, social workers, and pain management specialist Good spectrum of pain medication drugs Physiotherapy TENS therapy Behavioral/cognitive therapy Formation of national societies/support groups Acupuncture/acupressure many be beneficial Distraction and entertainment, including videos and other media Improved clinical outcomes in the management of SCD crisis Medical and health education of medical staff and patient on:
forms of and preventing exposure to hypoxia (ie, altitude, smoking) habits and the use of charcoal in heating within closed areas avoidance of excessive physical stress and competitive exercise avoidance of sudden changes in temperature avoidance of exposure to infection avoidance of dehydration SCA ¼ sickle-cell anemia; SCD ¼ sickle-cell disease; TENS= transcutatneous electrical nerve stimulation LMWH in Pregnancy and SCA LMWHs are regarded attractive alternatives to unfractionated heparin (UFH) as anticoagulants during pregnancy due to their clinical advantages and their association with a lower incidence of bleeding, osteoporosis, and heparin-induced thrombocytopenia (HIT). Many published reviews confirm that LMWHs are a safe alternative to UFH as anticoagulants during pregnancy. [74] [75] [76] [77] [78] [79] Tinzaparin sodium, the active ingredient of innohep 1 (Dupont, Wilmington, DE), has been used extensively in pregnant women at risk of developing or with a history of venous thromboembolism (VTE) and has proven to be a safe and effective pharmacologic agent. A recent multicenter, prospective, dosefinding clinical study report documented the safety and efficacy of Innohep treatment of high-risk pregnancy cases of various etiologies based on anti-Xa levels throughout the gestation period and beyond. 80 A treatment dose of 175 IU/kg per day as well as the prophylactic dose of 75 IU/kg per day reliably achieved target activities that were sufficient and safe, and there were stable gestational tinzaparin requirements (no dose adjustments). In addition, there were no apparent clinical effects of treatment on bone density.
The use of tinzaparin during crises in patients with SCA has been documented 8 ; however, the issue of its use during crises in pregnant patients with SCA has not been thoroughly investigated. Recent guidelines acknowledge that SCA pregnant patients are at risk of developing VTE and, accordingly, a prophylactic dose of LMWHs can be given throughout pregnancy and postpartum. 81 
Management During Labor
Generally, delivery can be accomplished vaginally with cesarean section reserved for obstetric indications. Spontaneous labor is preferable because sickle-cell crisis has been reported to be associated with induction of labor. There is concern that the use of prostaglandins may lead to cell sickling, and therefore, should be used with caution. 73 
Blood Transfusion
Prophylactic blood transfusions have been used to treat pregnant women who have sickle-cell disorders. Currently, their use is controversial. A comparative trial of prophylactic versus on demand-based transfusion showed no difference in prenatal outcome between the two groups. The group that was transfused had a lower incidence of painful crisis; however, other medical and obstetric complications occurred in equal frequency. 73 
Conclusions
Sickle-cell disease, with its burden of excruciating pain associated with sickle-cell crisis, is the most common globin gene disorder and a major health problem. The prediction in very early childhood of later severe disease could justify the early use of disease-modifying procedures or interventions, such as hydroxyurea treatment, chronic transfusions, or stem cell transplantation. The hazards of these treatments vary greatly, particularly as compared to preventive and supportive management alone. Accurate and reliable early predictors would provide the opportunity to better balance the risks of these interventions with risks of the disease itself, and might reduce the frequency of hospitalization and blood transfusion, the incidence of pain and the occurrence of acute chest syndrome and pulmonary hypertension in patients with SCD. A randomized, double-blind clinical study of the LMWH tinzaparin demonstrated significant and rapid pain resolution, underscoring the urgent need for additional therapeutic strategies designed to counteract the endothelial, inflammatory, hypercoagulation, and oxidative abnormalities associated with SCD. Currently, there is an unmet medical need for better management of SCD patients. Not covered by this review, but of special consideration in the management of SCD patients, are renal failure, addiction to opiates, and perioperative painful crisis management.
